One of the first trials assessing maintenance therapy with an immunotherapeutic agent is the cohort number four of the NCT00455572 trial, in which patients presenting with cancer/testis antigen MAGE-A3-positive NSCLCs received intramuscular injections of MAGE-A3 with the immunostimulant agent AS15. The gene discussed is MAGEA3; the disease is cancer.